Skip to main content
Erschienen in: Journal of Radiation Oncology 2/2017

03.05.2017 | Original Research

Temporal trends for adjuvant radiation utilization and their effect on survival for locally advanced (stage III) endometrial cancer in the USA

verfasst von: Chiachien Jake Wang, Alana Christie, Michael R. Folkert, Xian-Jin Xie, Kevin Albuquerque

Erschienen in: Journal of Radiation Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

Adjuvant radiotherapy improves locoregional control of stage III endometrial cancer (EC), but its role was challenged after Gynecologic Oncology Group (GOG) 122 demonstrated survival benefit with chemotherapy. This study describes the trends in adjuvant radiotherapy utilization for stage III endometrial cancer and assesses its association with survival outcomes.

Methods

We extracted 6913 patients with stage III endometrioid subtype EC (EEC) from the Surveillance, Epidemiology, and End Result (SEER) 18 Registry Research Database treated between 2004 and 2012. We retrospectively reviewed patient demographics, tumor characteristics, and clinical parameters. Temporal trend of radiation use was assessed by linear regression. Univariate Cox regression analysis followed by a multivariate modeling was used to analyze the impact of radiation on survival.

Results

Patients not receiving adjuvant radiotherapy and those receiving vaginal brachytherapy (VBT) alone in stage III EEC increased over study period (1.42%/year and 0.73%/year, respectively), but those with external beam radiation (EBRT) and combination radiotherapy decreased (−1.42%/year and −0.73%/year, respectively). Age, stage, grade, degree of lymph node dissection, and radiation utilization were found to impact overall and cancer-specific survival on multivariate analysis. Survival was improved with use of EBRT (HR 0.65, 95% CI 0.58–0.73, P < 0.001), VBT (HR 0.62, 95% CI 0.49–0.78, P < 0.001), and combination radiotherapy (HR 0.56, 95% CI 0.48–0.64, P < 0.001).

Conclusion

Based upon this analysis, omission of adjuvant radiation therapy has become more prevalent in stage III EEC patients, and this was associated with worse survival. Appropriate incorporation of radiotherapy in the management of these patients should be further explored in prospective studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Colombo N, Preti E, Landoni F et al (2013) Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi33–vi38CrossRefPubMed Colombo N, Preti E, Landoni F et al (2013) Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi33–vi38CrossRefPubMed
3.
Zurück zum Zitat Colombo N, Creutzberg C, Amant F et al (2015) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Radiother Oncol 117:559–581CrossRefPubMed Colombo N, Creutzberg C, Amant F et al (2015) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Radiother Oncol 117:559–581CrossRefPubMed
5.
Zurück zum Zitat Martinez A, Schray M, Podratz K et al (1989) Postoperative whole abdomino-pelvic irradiation for patients with high risk endometrial cancer. Int J Radiat Oncol Biol Phys 17:371–377CrossRefPubMed Martinez A, Schray M, Podratz K et al (1989) Postoperative whole abdomino-pelvic irradiation for patients with high risk endometrial cancer. Int J Radiat Oncol Biol Phys 17:371–377CrossRefPubMed
6.
Zurück zum Zitat Sutton G, Axelrod JH, Bundy BN et al (2005) Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 97:755–763CrossRefPubMed Sutton G, Axelrod JH, Bundy BN et al (2005) Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 97:755–763CrossRefPubMed
7.
Zurück zum Zitat Gibbons S, Martinez A, Schray M et al (1991) Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys 21:1019–1025CrossRefPubMed Gibbons S, Martinez A, Schray M et al (1991) Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys 21:1019–1025CrossRefPubMed
8.
Zurück zum Zitat Stewart KD, Martinez AA, Weiner S et al (2002) Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. Int J Radiat Oncol Biol Phys 54:527–535CrossRefPubMed Stewart KD, Martinez AA, Weiner S et al (2002) Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. Int J Radiat Oncol Biol Phys 54:527–535CrossRefPubMed
9.
Zurück zum Zitat Fleming GF, Brunetto VL, Cella D et al (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22:2159–2166CrossRefPubMed Fleming GF, Brunetto VL, Cella D et al (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22:2159–2166CrossRefPubMed
10.
Zurück zum Zitat Homesley HD, Filiaci V, Gibbons SK et al (2009) A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 112:543–552CrossRefPubMed Homesley HD, Filiaci V, Gibbons SK et al (2009) A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 112:543–552CrossRefPubMed
11.
Zurück zum Zitat Thigpen JT, Blessing JA, Homesley H et al (1989) Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 33:68–70CrossRefPubMed Thigpen JT, Blessing JA, Homesley H et al (1989) Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 33:68–70CrossRefPubMed
12.
Zurück zum Zitat Thigpen JT, Brady MF, Homesley HD et al (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22:3902–3908CrossRefPubMed Thigpen JT, Brady MF, Homesley HD et al (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22:3902–3908CrossRefPubMed
13.
Zurück zum Zitat Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44CrossRefPubMed Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44CrossRefPubMed
14.
Zurück zum Zitat Susumu N, Sagae S, Udagawa Y et al (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108:226–233CrossRefPubMed Susumu N, Sagae S, Udagawa Y et al (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108:226–233CrossRefPubMed
15.
Zurück zum Zitat Maggi R, Lissoni A, Spina F et al (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271CrossRefPubMedPubMedCentral Maggi R, Lissoni A, Spina F et al (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973–2012 varying) - Linked To County Attributes - Total U.S., 1969–2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission. Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973–2012 varying) - Linked To County Attributes - Total U.S., 1969–2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.
17.
Zurück zum Zitat Tiwari RC, Clegg LX, Zou Z (2006) Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res 15:547–569CrossRefPubMed Tiwari RC, Clegg LX, Zou Z (2006) Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res 15:547–569CrossRefPubMed
18.
Zurück zum Zitat Galaal K, Al Moundhri M, Bryant A et al (2014) Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev 5:CD010681 Galaal K, Al Moundhri M, Bryant A et al (2014) Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev 5:CD010681
19.
Zurück zum Zitat RyersonAB, EhemanCR, AltekruseSFet al.(1975–2012) Annual report to the nation on the status of cancer, featuring the increasing incidence of liver cancer. Cancer 2016 RyersonAB, EhemanCR, AltekruseSFet al.(1975–2012) Annual report to the nation on the status of cancer, featuring the increasing incidence of liver cancer. Cancer 2016
20.
Zurück zum Zitat Hogberg T, Signorelli M, de Oliveira CF et al (2010) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer 46:2422–2431CrossRefPubMedPubMedCentral Hogberg T, Signorelli M, de Oliveira CF et al (2010) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer 46:2422–2431CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Greven K, Winter K, Underhill K et al (2006) Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 103:155–159CrossRefPubMed Greven K, Winter K, Underhill K et al (2006) Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 103:155–159CrossRefPubMed
22.
Zurück zum Zitat Secord AA, Geller MA, Broadwater G et al (2013) A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol 128:65–70CrossRefPubMed Secord AA, Geller MA, Broadwater G et al (2013) A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol 128:65–70CrossRefPubMed
23.
Zurück zum Zitat Klopp AH, Jhingran A, Ramondetta L et al (2009) Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol 115:6–11CrossRefPubMed Klopp AH, Jhingran A, Ramondetta L et al (2009) Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol 115:6–11CrossRefPubMed
24.
Zurück zum Zitat Mundt AJ, McBride R, Rotmensch J et al (2001) Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 50:1145–1153CrossRefPubMed Mundt AJ, McBride R, Rotmensch J et al (2001) Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 50:1145–1153CrossRefPubMed
25.
Zurück zum Zitat Lee LJ, Viswanathan AN (2012) Combined chemotherapy and radiation improves survival for node-positive endometrial cancer. Gynecol Oncol 127:32–37CrossRefPubMedPubMedCentral Lee LJ, Viswanathan AN (2012) Combined chemotherapy and radiation improves survival for node-positive endometrial cancer. Gynecol Oncol 127:32–37CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Kuku S, Williams M, McCormack M (2013) Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. A single-institution retrospective study. Int J Gynecol Cancer 23:1056–1064CrossRefPubMed Kuku S, Williams M, McCormack M (2013) Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. A single-institution retrospective study. Int J Gynecol Cancer 23:1056–1064CrossRefPubMed
27.
Zurück zum Zitat Geller MA, Ivy JJ, Ghebre R et al (2011) A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 121:112–117CrossRefPubMed Geller MA, Ivy JJ, Ghebre R et al (2011) A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 121:112–117CrossRefPubMed
28.
Zurück zum Zitat Rauh-Hain JA, Pepin KJ, Meyer LA et al (2015) Management for elderly women with advanced-stage, high-grade endometrial cancer. Obstet Gynecol 126:1198–1206CrossRefPubMed Rauh-Hain JA, Pepin KJ, Meyer LA et al (2015) Management for elderly women with advanced-stage, high-grade endometrial cancer. Obstet Gynecol 126:1198–1206CrossRefPubMed
29.
Zurück zum Zitat BootheD, OrtonA, OdeiBet al. Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: patterns of care and impact on overall survival. Gynecol Oncol 2016. BootheD, OrtonA, OdeiBet al. Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: patterns of care and impact on overall survival. Gynecol Oncol 2016.
30.
Zurück zum Zitat Filiaci VLAC, Cho J, Kim JW, DiSilvestro PA, O’Malley D, Rutherford TJ, Van Le L, Randall ME (2014) A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial. Gynecol Oncol 134:1CrossRef Filiaci VLAC, Cho J, Kim JW, DiSilvestro PA, O’Malley D, Rutherford TJ, Van Le L, Randall ME (2014) A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial. Gynecol Oncol 134:1CrossRef
Metadaten
Titel
Temporal trends for adjuvant radiation utilization and their effect on survival for locally advanced (stage III) endometrial cancer in the USA
verfasst von
Chiachien Jake Wang
Alana Christie
Michael R. Folkert
Xian-Jin Xie
Kevin Albuquerque
Publikationsdatum
03.05.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 2/2017
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-017-0306-7

Weitere Artikel der Ausgabe 2/2017

Journal of Radiation Oncology 2/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.